Products
Tabirafusp Biosimilar Antibody Fusion Protein (IL-6) for Research
Cat No.: GMP-Bios-INN-1405
Anti-IL6 therapeutic antibody (Pre-made Tabirafusp biosimilar,Antibody Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tabirafusp (development code KSI-501) is an antibody fusion protein comprising fragments of the extracellular domains of human vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2), targeting vascular endothial growth factors. It is developed by Kodiak Sciences for Wet age-related macular degeneration, Diabetic macular oedema and Dry age-related macular degeneration. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1405-1mg | 1mg | 3090 |
| GMP-Bios-INN-1405-10mg | 10mg | |
| GMP-Bios-INN-1405-100mg | 100mg | |
| GMP-Bios-INN-1405-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tabirafusp biosimilar, Antibody Fusion Protein targeting IL6: Recombinant therapeutic protein targeting BSF-2/BSF2/CDF/HGF |
| INN Name | Tabirafusp |
| Target | IL6 |
| Format | Antibody Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Kodiak Sciences |
| Conditions Approved | na |
| Conditions Active | Wet age-related macular degeneration;Diabetic macular oedema;Dry age-related macular degeneration |
| Conditions Discontinued | Uveitis |
| Production | na |
| Development Tech | na |
